期刊文献+

5种药物降眼压效果比较 被引量:1

Ocular Hypotensive Efficacy of Five Drugs:A Comparative Study
原文传递
导出
摘要 目的:比较噻吗洛尔、溴莫尼定、倍他洛尔、布林佐胺和曲伏前列腺素5种滴眼液的降眼压效果。方法:将原发性开角型青光眼、高眼压患者随机分为5组,其中噻吗洛尔组18例,溴莫尼定组13例,倍他洛尔组16例,布林佐胺组12例和曲伏前列腺素组10例,分别使用相应滴眼液,均治疗4周,测量用药前、后的眼压值。结果:5组患者用药4周眼压值均有明显下降,下降幅度依次为28.0%、28.9%、14.9%、16.1%和33.8%,且都产生了不同程度的副作用。结论:临床应根据各降眼压药的降眼压效果及副作用,合理选择使用。 OBJECTIVE: To evaluate the ocular hypotensive efficacies of five kinds of eye drops (Timolol, Brimonidine, Betaxolol, Brinzolamide, and travoprost). METHODS: Patients with primary open angle glaucoma (POAG) or ocular hyper- tension(OH) were randomly divided into 5 groups: Timolol(n = 18), Brimonidine(n = 13), Betaxolol(n = 16), Brinzolamide (n = 12) or travoprost(n = 10) . The course of treatment was 4 weeks for all the 5 groups. The intraocular pressure (IOP) before and after the treatment was measured. RESULTS: After treatment for 4 weeks, the IOPs in five groups decreased markedly, down 28.0%, 28.9%, 14.9%, 16.1%, and 33.8%, respectively, and all the 5 drugs resulted in adverse effects of different degree. CONCLUSION: The ocular hypotensive drugs should be used rationally by taking consideration of their oc- ular hypotensive efficacy and side effects.
出处 《中国药房》 CAS CSCD 北大核心 2009年第17期1330-1332,共3页 China Pharmacy
关键词 治疗应用 青光眼 高眼压 药物疗法 Therapeutic use Glaucoma Ocular hypertension Drug therapy
  • 相关文献

参考文献7

二级参考文献22

  • 1Desantis L. Preclinical overview of brinzolamide[ J]. Surv Ophthalmol,2000,44(2) :S119.
  • 2Klemm M,Zeitz O,Reuss J, et al.Therapy of normal tension glaucoma: effect of brinzolamide on ocular haemodynamics[ J ]. Klin Monatsbl Augenheilkd, 2003,220 ( 5 ): 330.
  • 3刘苹摘 边强校.青光眼治疗药Brinzolamide.国外医药:合成药.生化药.制剂分册,2000,21(1):24-24.
  • 4Preoteasa D, Mocanu C.Efficacy of ophthalmic suspension of Brinzolamide(Azopt) in the primary or combined therapy for patients with hypertensive glaucomas[ J]. Oftalmologia, 2001,54(4): 20.
  • 5Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension(Azopt)as a primary therapy in patients with open-angle glaucoma or ocular hypertension[ J ]. Surv Ophthalmol, 2000,44(2): s155.
  • 6Silver LH. Clinical efficacy and safety of brinzolamide(Azopt), a new topical carbonic anhydrase in hibitor for primary open-angle glaucoma and ocular hypertension[J]. Am J Ophthalmol, 1998,126(3) :400.
  • 7March WF, Ochsner KI.The long-term safety and efficacy of brinzolamide 1.0% (Azopt)in patients with primary open-angle glaucoma or ocular hypertension The Brinzolamide Long-Term Therapy Study Group [J] .Am J Ophthalmol, 2000 ,129 ( 2 ) : 136.
  • 8Shin D.Brinzolamide Adjunctive Therapy Study Group. Adjunctive therapy with brinzolamide 1% ophthalmic suspension in paients with open-angle or ocular hypertension maintained on timolol therapy[ J].Surv Ophthalmol , 2000,44: S163.
  • 9Dreyer EB.A proposed role for excitotoxicity in glaucoma[J].J Glaucoma,1998,7:62-67.
  • 10Osborno NN,Chidlow G,Nash MS,et al.The potential of neuroprotection in glaucona treatment[J].Curr Opin Ophthalmol,1999,10:82-92.

共引文献26

同被引文献16

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部